Jiangsu Bioperfectus Technologies Co Ltd
688399
Company Profile
Business description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
Contact
3rd floor, Block G19, No.1 Yaocheng Avenue
Jiangsu
Taizhou
CHNT: +86 52386201616
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
581
Stocks News & Analysis
stocks
A closer look at US tech earnings
How a handful of tech giants continue to shape market returns and what investors should watch next.
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
Energy provider lifts earnings guidance on stronger power plant performance.
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.40 | 32.70 | -0.37% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,486.63 | 79.79 | 0.30% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,784.12 | 366.24 | 0.59% |
| NZX 50 Index | 13,059.74 | 150.74 | -1.14% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,683.00 | 28.30 | -0.32% |
| SSE Composite Index | 4,208.00 | 17.02 | -0.40% |